Search
Ensartinib
go.drugbank.com/drugs/DB14860ApprovedInvestigational[A273963, A273958] Ensartinib is a first-line treatment for anaplastic lymphoma kinase (ALK)-mutated non-small cell lung cancer (NSCLC). … Non-small cell lung cancer (NSCLC) is one of the most frequent subtypes of lung cancers and encompasses a variety of different lung cancers, with notable ones being adenocarcinoma, squamous cell carcinoma
Categories: P-glycoprotein substrates, Heterocyclic Compounds, 1-RingCefiderocol
go.drugbank.com/drugs/DB14879ApprovedInvestigationalCefiderocol is a cephalosporin antibacterial drug and exerts a mechanism of action similar to other β-lactam antibiotics. … [A189150] A concern noted in the trial was a 0.3% higher rate of all cause mortality, the cause of which has not been determined.
Categories: Heterocyclic Compounds, 2-Ring, Compounds used in a research, industrial, or household settingRitlecitinib
go.drugbank.com/drugs/DB14924ApprovedInvestigational[A260122,A260127] Ritlecitinib binds covalently to Cys-909 of JAK3, a site where other JAK isoforms have a serine residue. … Ritlecitinib (PF-06651600) is a highly selective inhibitor of Janus kinase 3 (JAK3) and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) kinase family.
Synonyms: 2-propen-1-one, 1-((2S,5R)-2-methyl-5-(7H-pyrrolo(2,3-D)pyrimidin-4-ylamino)-1-piperidinyl)-Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InhibitorsPyrotinib
go.drugbank.com/drugs/DB14993InvestigationalPyrotinib is under investigation in clinical trial NCT03756064 (Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer).
Categories: Heterocyclic Compounds, 2-RingDaridorexant
go.drugbank.com/drugs/DB15031ApprovedInvestigationalConventional treatments for insomnia include drugs targeting gamma-aminobutyric acid type-A (GABA-A), serotonin, histamine, or melatonin receptors; however, undesirable side effects are frequently reported … Daridorexant, formerly known as nemorexant, is a selective dual orexin receptor antagonist used to treat insomnia.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesZanubrutinib
go.drugbank.com/drugs/DB15035ApprovedInvestigational[A187967] BTK is an enzyme that plays a role in oncogenic signalling pathways, promoting the survival and proliferation of malignant B cells. … trial whose tumour is entirely or partially destroyed by a drug.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2B6 Substrates with a Narrow Therapeutic IndexMipicoledine
go.drugbank.com/drugs/DB15075InvestigationalMipicoledine is under investigation in clinical trial NCT01048008 (Study of 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Advanced Cancer).
Synonyms: (3.BETA.)-CHOLEST-5-EN-3-YL 3,5-DICHLORO-2-METHOXY-6-(TRICHLOROMETHYL)PYRIDIN-4-YL CARBONATE, CHOLEST-5-EN-3-OL (3.BETA.)-, 3-(3,5-DICHLORO-2-METHOXY-6-(TRICHLOROMETHYL)-4-PYRIDINYL CARBONATE)Categories: P-glycoprotein substratesUpadacitinib
go.drugbank.com/drugs/DB15091ApprovedInvestigationalUpadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. … Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints.
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsDexpramipexole
go.drugbank.com/drugs/DB15130Investigationaltrial NCT01511029 (Study to Evaluate the QTC Interval in Healthy Volunteers Dosed With Dexpramipexole (QTC = Electrocardiogram (ECG) Interval Measured From the Onset of the QRS Complex to the End of the T
Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-RingTepotinib
go.drugbank.com/drugs/DB15133ApprovedInvestigationalTepotinib is a MET tyrosine kinase inhibitor intended to treat a variety of MET-overexpressing solid tumors. … [A228058] MET is a desirable target in the treatment of certain solid tumors as it appears to play a critical role, both directly and indirectly, in the growth and proliferation of tumors in which it is
Categories: MATE 1 Inhibitors, MATE 2 Inhibitors